» Articles » PMID: 25406751

Using the TIME Model in Spectrum to Estimate Tuberculosis-HIV Incidence and Mortality

Overview
Journal AIDS
Date 2014 Nov 20
PMID 25406751
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Reliable estimates of the joint burden of HIV and tuberculosis epidemics are crucial to planning strategic global and national tuberculosis responses. Prior to the Global Tuberculosis Report 2013, the Global Tuberculosis Programme (GTB) released estimates for tuberculosis-HIV incidence at the global level only. Neither GTB nor United Nations Programme on HIV/AIDS (UNAIDS) published country specific estimates for tuberculosis-HIV mortality. We used a regression approach that combined all available data from GTB and UNAIDS in order to estimate tuberculosis-HIV incidence and mortality at country level.

Methods: A regression method was devised to relate CD4 dynamics (based on national Spectrum files) to an increased relative risk (RR) of tuberculosis disease. The objective function is based on least squares and incorporates all available country-level estimates of tuberculosis-HIV incidence. Global regression parameters, obtained from averaging results over countries with population survey estimates for tuberculosis-HIV burden, were applied to countries with no survey tuberculosis-HIV incidence estimates.

Results: The method produced results that are in reasonably close agreement with existing GTB estimates for global tuberculosis-HIV burden. It estimated that tuberculosis-HIV accounts for 12.6% of global tuberculosis incidence, 21.3% of all tuberculosis deaths, and 20% of all HIV deaths as estimated by the Spectrum AIDS Impact Module (AIM). Regional estimates show the highest absolute incidence burden in East and Southeast Asia, and the highest per capita burden in sub-Saharan Africa, where between 12.5% (Central sub-Saharan Africa) and 60.6% (Southern sub-Saharan Africa) of all tuberculosis disease occurs in people living with HIV (PLWH). Tuberculosis mortality follows a similar pattern, except that a disproportionate percentage of global tuberculosis deaths (12.1%) relative to global incidence (8.7%) occurred in Southern sub-Saharan Africa.

Conclusion: The disaggregation of tuberculosis incidence using a regression method on RR of tuberculosis disease and all available data on HIV burden (from UNAIDS) and tuberculosis-HIV testing (survey, sentinel and routine surveillance data) produces results that closely match GTB estimates for 2011. The tuberculosis-HIV incidence and mortality results were published in the Global Tuberculosis Report 2013. Several limitations of and potential improvements to the process are suggested.

Citing Articles

Modelling the impact of CD4 testing on mortality from TB and cryptococcal meningitis among patients with advanced HIV disease in nine countries.

Oboho I, Paulin H, Corcoran C, Hamilton M, Jordan A, Kirking H J Int AIDS Soc. 2023; 26(3):e26070.

PMID: 36880429 PMC: 9989935. DOI: 10.1002/jia2.26070.


CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis.

Ellis P, Martin W, Dodd P PeerJ. 2017; 5:e4165.

PMID: 29259846 PMC: 5733368. DOI: 10.7717/peerj.4165.


TIME Impact - a new user-friendly tuberculosis (TB) model to inform TB policy decisions.

Houben R, Lalli M, Sumner T, Hamilton M, Pedrazzoli D, Bonsu F BMC Med. 2016; 14:56.

PMID: 27012808 PMC: 4806495. DOI: 10.1186/s12916-016-0608-4.


Incorporating Demand and Supply Constraints into Economic Evaluations in Low-Income and Middle-Income Countries.

Vassall A, Mangham-Jefferies L, Gomez G, Pitt C, Foster N Health Econ. 2016; 25 Suppl 1:95-115.

PMID: 26786617 PMC: 5042074. DOI: 10.1002/hec.3306.


Updates to the spectrum model to estimate key HIV indicators for adults and children.

Stover J, Andreev K, Slaymaker E, Gopalappa C, Sabin K, Velasquez C AIDS. 2014; 28 Suppl 4:S427-34.

PMID: 25406748 PMC: 4247263. DOI: 10.1097/QAD.0000000000000483.


References
1.
ONeill K, Takane M, Sheffel A, Abou-Zahr C, Boerma T . Monitoring service delivery for universal health coverage: the Service Availability and Readiness Assessment. Bull World Health Organ. 2013; 91(12):923-31. PMC: 3845262. DOI: 10.2471/BLT.12.116798. View

2.
Odone A, Amadasi S, White R, Cohen T, Grant A, Houben R . The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. PLoS One. 2014; 9(11):e112017. PMC: 4229142. DOI: 10.1371/journal.pone.0112017. View

3.
Mukadi Y, Maher D, Harries A . Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001; 15(2):143-52. DOI: 10.1097/00002030-200101260-00002. View

4.
Uplekar M, Pathania V, Raviglione M . Private practitioners and public health: weak links in tuberculosis control. Lancet. 2001; 358(9285):912-6. DOI: 10.1016/S0140-6736(01)06076-7. View

5.
Corbett E, Watt C, Walker N, Maher D, Williams B, Raviglione M . The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163(9):1009-21. DOI: 10.1001/archinte.163.9.1009. View